Personalised transcranial alternating current stimulation as a novel therapeutic treatment for post-traumatic stress disorder

Not Applicable

Conditions: PTSD
Mental Health - Other mental health disorders

Registration Number: ACTRN12624000889550

Lead Sponsor: Australian National University

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: ot yet recruiting

Sex: All

Target Recruitment: 26

Inclusion Criteria

Aged between 18-80 years of age
Clinician-Administered PTSD Scale (CAPS-5) total score of moderate-severe (greater than or equal to 20)
No change or initiation of new medication (antidepressant or other psychoactive) in the four weeks prior to screening
Demonstrated capacity to give informed consent

Exclusion Criteria

Inability to provide informed consent
Medically unstable
Concomitant active neurological disorder
Individuals who are pregnant or breastfeeding
Active suicidal intent
Any psychotic disorder or current active psychotic symptoms
Meets criteria for current DSM 5 alcohol or substance dependence
Borderline personality disorder judged by an investigator to prevent appropriate engagement in the study
Individuals who have intracranial implants
Another AXIS I or II disorder judged to impact on the likelihood of response to treatment

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Changes in Alpha power between active treatment and sham[Measured using EEG Pre-treatment block and post-treatment block for personalised alpha-tACS and sham-tACS]

Secondary Outcome Measures

Name	Time	Method
Changes in post-traumatic stress disorder (PTSD) severity[Measured using clinician administered PTSD Scale (CAPS-5) Baseline, post-treatment block 1, pre- and post-treatment block 2 and at 4-week follow-up];Changes in PTSD severity[Measured using self-reported PTSD Checklist (PCL-5) Baseline, post-treatment block 1, pre- and post-treatment block 2 and at 4-week follow-up];Changes in clinical severity of depression [Clinician rated Montgomery-Asberg Depression Rating Scale (MADRS) Baseline, post-treatment block 1, pre- and post-treatment bloc 2 and at 4-week follow-up];Changes in participants' quality of life[Assessed using self-report questionnaire Assessment of Quality-of-Life Scale Baseline, post-treatment block 1, pre- and post-treatment bloc 2 and at 4-week follow-up]